Navigation Links
CV Therapeutics Reports 2008 Second Quarter Financial Results
Date:7/31/2008

- Ranexa Revenue Grows 15 Percent Quarter-over-Quarter -

PALO ALTO, Calif., July 31 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) today reported financial results for the second quarter ended June 30, 2008.

For the quarter ended June 30, 2008, the Company reported a net loss of $4.3 million, or $0.07 per share. This compares to a net loss of $31.9 million, or $0.53 per share, for the prior quarter ended March 31, 2008 and $57.6 million, or $0.97 per share, for the same quarter in 2007.

For the quarter ended June 30, 2008, the Company recorded total revenues of $51.6 million which consisted of $25.4 million of net product sales of Ranexa(R) (ranolazine extended-release tablets), $4.0 million of royalty revenue and $22.2 million of license, collaboration and other revenue. The $25.4 million of net product sales for sales of Ranexa represents an increase of 15 percent compared to the $22.0 million of net product sales recorded in the prior quarter ended March 31, 2008. The $4.0 million of royalty revenue includes $2.6 million of amortization of our $175.0 million upfront payment earned from an investment trust related to TPG-Axon Capital in exchange for rights to 50 percent of our royalty on North American sales of Lexiscan(TM) (regadenoson) injection and $1.3 million of Lexiscan(TM) royalty revenue. The $22.2 million of license, collaboration and other revenue includes $12.0 million relating to a milestone payment from Astellas Pharma US. Inc. (Astellas) associated with the U.S. Food and Drug Administration (FDA) approval for Lexiscan(TM) and $10.0 million relating to a milestone payment from TPG-Axon Capital associated with the commercial launch of Lexiscan(TM).

Costs and expenses were $56
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 2013 New interactive learning ... thought leaders of the medical device industry at ... and expo, from June 18-20 in ... http://photos.prnewswire.com/prnh/20130517/613829 ) , These all-new ... professionals practical presentations and implementable solutions on the ...
(Date:5/17/2013)... May 17, 2013 Men’s skin is biologically ... La-roche Posay ) and has been known to react more ... men may be far from puberty, other acne causing factors ... causing breakouts, and threatening skin with unsightly acne scars. Adult ... Men’s Health on how to reduce and prevent ...
(Date:5/17/2013)... May 17, 2013 Tooth decay is an ... active signs of the disease. The World Health Organization says ... 100% of adults have cavities. What are the long-term effects ... showing a strong connection between the oral bacterial imbalance and ... disease so rampant, yet it is also 100% preventable? Answer: ...
(Date:5/16/2013)... (PRWEB) May 16, 2013 A ... portable models, from Cole-Parmer is designed to meet ... line includes: , The new Cole-Parmer® MS-3400 ... workhorses in the lab. They ensure a powerful ... plasma specimen separation. Their standard four-place swinging buckets ...
Breaking Biology Technology:MedTech Innovate Seminars: New Interactive Learning Forums at 2013 MD&M East 2Adult Acne Treatment, Probiotic Action Shares New Insight on Why Men’s Skin Scars from Acne and How to Prevent It 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 3Cole-Parmer Offers Enhanced Selection of Centrifuges 2
... data on lead NNRTI, RDEA806, and next generation compounds to be ... ... Calif., Jan. 29 Ardea Biosciences,Inc. (Nasdaq: RDEA ) today ... family of compounds,including RDEA806, RDEA427 and RDEA640, will be presented during ...
... Oncolytics Biotech Inc. (TSX:,ONC, NASDAQ: ONCY) ("Oncolytics") ... of Neoplastic Cells from Mixed Cellular,Compositions using ... cancer cells ex vivo from blood stem ... modified vaccinia viruses, herpes simplex,viruses, parapoxviruses and ...
... CALGARY, Jan. 29 /PRNewswire-FirstCall/ - SemBioSys Genetics ... of therapeutic,proteins for metabolic and cardiovascular diseases, today ... The Instituto de Agrobiotecnologia,Rosario S.A. (INDEAR) based in ... by Bio Sidus AG S.A. and Bioceres S.A. ...
Cached Biology Technology:Ardea Biosciences to Present Preclinical Data on Three HIV Non-Nucleoside Reverse Transcriptase Inhibitors During 15th Annual Conference on Retroviruses and Opportunistic Infections 2Ardea Biosciences to Present Preclinical Data on Three HIV Non-Nucleoside Reverse Transcriptase Inhibitors During 15th Annual Conference on Retroviruses and Opportunistic Infections 3Oncolytics Biotech Inc. Announces Issuance of 8th Canadian Patent 2SemBioSys signs option agreement for safflower-produced food ingredient 2SemBioSys signs option agreement for safflower-produced food ingredient 3
(Date:5/16/2013)... genome-wide analysis (GWA), where the entirety of an individual,s ... or variants which can cause health problems is a ... can also pose major ethical problems if used incorrectly, ... Genetics (ESHG) published on line today (16 May 2013) ... Many services based on whole genome and on exome* ...
(Date:5/16/2013)... outside of the gym. But doctors use the human pulse ... Bao, a professor of chemical engineering at Stanford, has developed ... wider than a postage stamp. The flexible skin-like monitor, worn ... to help doctors detect stiff arteries and cardiovascular problems. , ... heart health and provide doctors a safer method of measuring ...
(Date:5/15/2013)... touting its benefit in moderating gout risk, new research ... not reduce uric acid (urate) levels to a clinically ... supplementation, alone or in combination with allopurinol, appears to ... in gout patients according to the results published in ... & Rheumatism . , Gout is an inflammatory ...
Breaking Biology News(10 mins):European Society of Human Genetics urges caution over use of new genetic sequencing techniques 2Stanford engineers monitor heart health using paper-thin flexible 'skin' 2Stanford engineers monitor heart health using paper-thin flexible 'skin' 3Vitamin C does not lower uric acid levels in gout patients 2
... the 2007 American Society for Microbiology (ASM) ICAAC Young ... Jason T. Blackard, Ph.D., Research Assistant Professor in the ... Medicine. Dr. Blackard is being honored for his ... Dr. Blackard is a highly qualified researcher, whose current ...
... 2007 American Society for Microbiology (ASM) ICAAC Young Investigator ... Ton-That, Ph.D., Assistant Professor in the Department of Molecular, ... Dr. Ton-That is being honored for his research ... Ton-Thats research is highly regarded, and has been published ...
... September 13, 2007 One of the 2007 American Society ... Merck and Company, Inc., U.S. Human Health, will be ... Professor in Pediatrics, Division of Pulmonary Pediatrics, Childrens Hospital ... is being honored for his research excellence in microbiology ...
Cached Biology News:
...
Rabbit polyclonal to ZNF261 ( Abpromise for all tested applications). entrezGeneID: 9203 SwissProtID: Q14202...
...
sTNF-receptor I Polyclonal Antibody 100 ug affinity purified rabbit anti-human sTNF-receptor I polyclonal antibody. Performs well in WB/Elisa/Neutralization....
Biology Products: